Grants approved from February 2016 cycle set new record. The FSH Society has committed $648,774 in funding to five research projects that aim to break new ground in the search… Read More »
FSH Society commits over $1.38 million to research in 2016
New FSHD biotech launched with $55 million
From BusinessWire CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will… Read More »
Mouse grows a human muscle
With a little zap, transplanted human cells flourish in a mouse By June Kinoshita, FSH Society It’s like something out of Dr. Frankenstein’s underground laboratory, but a University of Maryland… Read More »
FSH Society Awards Grant to Establish Clinical Trial Research Network for FSHD
(PRWEB) JUNE 14, 2016 The FSH Society, a nonprofit, patient-driven organization that supports research and education for individuals with facioscapulohumeral muscular dystrophy (FSHD) and their families, today announced that it… Read More »
aTyr Pharma to advance Resolaris™ clinical programs
The San Diego-based biotech company, aTyr Pharma, Inc., released findings on March 30, 2016, from a Phase 1b/2 clinical trial of its experimental therapy Resolaris in adult facioscapulohumeral muscular dystrophy (FSHD) patients. While… Read More »